Vitruvias Thyroid Tablets Superpotency Recall
Analysis based on 9 articles · First reported Aug 25, 2026 · Last updated Aug 26, 2026
The recall may modestly affect Vitruvias Therapeutics' reputation and sales, though the limited scope (one lot) and lack of reported adverse events mitigate financial impact. The broader scrutiny on thyroid medications could influence regulatory oversight and consumer confidence in the sector.
Vitruvias Therapeutics voluntarily recalled one lot (504950) of Thyroid Tablets, USP 30 mg, distributed nationwide in the U.S., after testing indicated the tablets could be 'superpotent,' posing a risk of hyperthyroidism. The recall was announced by the FDA on August 24, 2026, and affects 3,655 units, of which 1,955 were sold. The company has not received reports of adverse events. Patients are advised to consult healthcare providers before discontinuing use. The recall is being conducted with FDA knowledge, and wholesalers are being notified to stop distribution and arrange destruction. The FDA also recently classified a separate recall of Levothyroxine Sodium Tablets by Intas Pharmaceuticals as Class II due to subpotency, and sent a warning letter to Intas Pharmaceuticals regarding manufacturing practices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard